CD4 and cancer: Another commonly used approach for confirming specific immune cell involvement in the rejection of 5TGM1‐Samsn1 cancer cells would be the co‐administration of neutralizing antibodies such as either anti‐CD4 and/or anti‐CD8 to target T‐cell subsets, or anti‐asialoGM1/anti‐NK1.1 to target NK cells,64, 65 some of these antibodies should enable the 5TGM1‐Samsn1 cancers to become established in Samsn1−/− hosts.